7,376.86

+23.13

+0.31%

51,285.73

-237.37

-0.46%

24,579.42

+264.42

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

74,265.53

-1,406.03

-1.86%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Exicure, Inc. (XCUR)

0.9498 +0.0597 (+6.71%)

At close: November 6 at 4:00:00 PM EST

Loading Chart for XCUR

Chart Range Bar

Interval:

In partnership with ChartIQ

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

Exicure Announces Board and Committee Changes

Exicure Announces Board and Committee Changes

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Mobilize your Website

View Site in Mobile | Classic

Share by: